Ireland· IE-PA-EU/1/16/1125/001
CINQAERO 10 mg/mL concentrate for solution for infusion
A medicinal product containing reslizumab, registered in Ireland by Teva B.V..
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Reslizumab
- Manufacturer
- Teva B.V.
- Country
- Ireland (IE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/16/1125/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Reslizumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCINQAEROTeva B.V., Haarlem
- FinlandCINQAEROTeva B.V.
- BelgiumCinqaero 10 mg/mlTeva
- United StatesCINQAIRTeva Respiratory, LLC
- IcelandCinqaeroTeva B.V.*
- PolandCinqaeroTeva B.V.
- SwedenCINQAERO 10 mg/ml Koncentrat till infusionsvätska, lösningTeva B.V.
- SwitzerlandCinqaero 100 mg/10 mL, Konzentrat zur Herstellung einer InfusionslösungTeva Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Cinqaero
- Iceland · Cinqaero
- Liechtenstein · Cinqaero
- Norway · Cinqaero
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e84ad421-9d26-40f9-846c-79cad84bdf22 GET /v1/drugs/e84ad421-9d26-40f9-846c-79cad84bdf22?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": null,
"strength": null,
"pa_number": "EU/1/16/1125/001",
"substances": [
"Reslizumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about reslizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.